



SCIEX

Quantitative and qualitative determination of 130 novel psychoactive substances in whole human blood

Scott Krepich¹, Craig M. Butt¹, and Pierre Negri¹

¹ SCIEX, USA

This technical note describes the quantitation of 130 novel psychoactive substances [NPS] in human whole blood, achieving in-sample limits of quantitation [LOQs] down to 0.1 ng/mL for most compounds using an MRM acquisition method. In addition, using the QTRAP technology of the SCIEX 5500+ system, compound detection confidence was improved using enhanced product ion [EPI] scans which enabled MS/MS library matching [Figure 1]. Most NPS showed positive MS/MS matches against a user-generated reference standard library in the 0.1 ng/mL calibrator, demonstrating good sensitivity and applicability for real-world samples. Using a standalone MRM method, good quantitative performance was shown in matrix spikes with mean accuracies between 80% and 120% and precision <10%CV for most NPS. In addition, the method demonstrated chromatographic separation for 24 out of 29 isobaric NPS groups. The acquisition of full scan MS/MS spectra distinguished most co-eluting isobaric groups, providing an added level of confidence for compound confirmation.

Key benefits for the analysis of NPSs in human whole blood using the SCIEX 5500+ system

Broad applicability. Routine, robust screening of 130 NPSs in human whole blood covering a wide diversity of NPS classes

Isobar separation. False positives minimized with the chromatographic separation of 24 out of 29 isobaric groups

Trace-level sensitivity. NPS were quantifiable in sample down to at least 0.1 ng/mL [in-sample] except for two compounds

Good LOQ quantitative performance. Mean accuracies were mostly between 80-120%, mean precision was mostly <10%CV

Enhanced detection confidence. EPI scans acquired high-quality MS/MS spectra for library matching against a user-generated database of reference standards. 122 out of 130 NPS showed a positive, accurate library match in the 0.1 ng/mL calibrator

Para-fluorofentanyl





Figure 1. Extracted ion chromatogram (XIC) and MS/MS spectrum from MRM-DDA-EPI scan for para-fluorofentanyl in the 0.1 ng/mL calibrator. Detection was confirmed through MS/MS library matching with a Fit score of 100 against the custom-generated NPS MS/MS library.

Introduction

NPS comprise a diverse class of chemicals and are analogues of controlled drugs and pharmaceuticals or newly synthesized compounds.¹ These novel drugs are often designed with the intention to mimic the effects of known controlled substances.¹ Recent years have seen a proliferation of NPS in the illicit drug market and they are well-recognized as significant public health concerns.

The diversity and complexity of NPS present a significant challenge for forensic toxicology workflows.² A robust screening workflow must be comprehensive, sensitive and possess a high degree of selectivity to minimize interferences from biological matrices. Further, large NPS panels are difficult due to the presence multiple isobaric chemicals, requiring chromatographic separation to avoid false positive detections. Finally, screening workflows must be adaptable to meet the constant discovery of new NPS chemicals.

In this technical note, we present a comprehensive, robust method for analyzing 130 NPS compounds in human whole blood using a simple protein precipitation sample preparation procedure and the SCIEX 5500+ system. Two workflows are presented. The first workflow used a traditional MRM acquisition method to achieve sub-ng/mL sensitivity in whole blood. The second method used data dependent acquisition (DDA) with an MRM survey scan to trigger EPI-based MS/MS, combined with MS/MS spectral library matching, to increase NPS detection confidence.

Methods

Target analytes: The target analytes comprised 130 NPS compounds of which 22 were stimulants, 16 were hallucinogens, 6 were dissociatives, 45 were synthetic opioids, 13 were benzodiazepines and 28 were synthetic cannabinoids [including cannabinoids]. Target analytes were purchased from Cerilliant Corporation (Round Rock, TX) and Cayman Chemical Company (Ann Arbor, MI). A master stock solution of all 130 NPS (1000 ng/mL) was prepared in methanol using seven individual mix solutions. The master stock solution was then used to make 3 intermediate stock solutions at 1, 10 and 100 ng/mL in whole blood.

Calibrator preparation: The 3 stock solutions in human whole blood were used to prepare a series of 9 calibrator solutions covering concentrations of 0.1-50 ng/mL [0.1, 0.25, 0.5, 1.0, 2.5, 5.0, 10, 25, and 50 ng/mL] for most analytes. The concentration range for alpha PPP was 0.01-5 ng/mL and 0.04-20 ng/mL for U-48800. The following components had one or both transitions calibrated only up to 25 ng/mL due to detector saturation: 4-APB, 3-chlorocathinone, deschloronorketamine, 4F-pentedrone, N-methyl-hexylone, bentazepam, 3-fluoro-N-ethylbuphenedrone, N-ethyl heptedrone, 5-MeO-MiPT, N-butyl hexedrone, flunitrazepam, PCE, para-methyl AP-237, furanyl UF-17, nitrazepam, 4F-MDMB-BICA, tenocyclidine, despropionyl ortho-fluorofentanyl, ADB-BINACA, N-piperidinyl etonitazine, ADB-4EN-PINACA, 5F-EMB-PICA, 5F-BZ0-POXIZID [5F-MDA-19], 4CN-CUMYL-BINACA, 4F-MDMB-BINACA, 4'-hydroxy nitazene, 5F-MDMB-PICA, ADB-PHETINACA, clonitazene.

Sample preparation: NPS were extracted from 200 µL of the spiked human whole blood mixtures using a protein precipitation procedure with acetonitrile. The protein precipitation procedure is summarized in **Figure 2**.

LC chromatography: Chromatographic separation was performed using an ExionLC system and the [Phenomenex Kinetex C18 column](#) [50 x 3.0mm, 2.6 µm, 00B-4462-Y0]. Mobile phase A [MPA] was 5mM ammonium formate in water with 0.1% [v/v] formic acid and mobile phase B [MPB] was 50:50 [v/v] methanol/acetonitrile with 0.1% [v/v] formic acid. The LC gradient program is presented in **Table 1**. The injection volume was 10 µL, the column oven was 30°C, the LC flow rate was 0.4 mL/min and the total LC runtime was 15.5 min.




Figure 2. Protein precipitation sample preparation procedure for the extraction of NPS from human whole blood.

Table 1: Chromatographic gradient for the analysis of NPS in human whole blood using the SCIEX 5500+ system.

| Time [min] | Mobile phase A [%] | Mobile phase B [%] |
|------------|--------------------|--------------------|
| 0.0 | 100 | 0 |
| 1.0 | 95 | 5 |
| 10 | 5 | 95 |
| 13 | 5 | 95 |
| 13.5 | 95 | 5 |
| 15.5 | 95 | 5 |

Mass spectrometry: Sample analysis was performed on a [SCIEX 5500+ system](#) with a [Turbo V ion source](#) and an electrospray ionization (ESI) probe operated in positive mode. Compound-specific and ion source parameters were manually optimized. Source and gas conditions are presented in [Table 2](#), and compound-specific parameters are in the Supporting Information. Two MRMs per compound were monitored except for 4F-ABINACA N-butanoic acid which showed only 1 product ion. The scheduled MRM (sMRM) algorithm in the SCIEX OS software was used to maximize dwell times and optimize the number of data points acquired across the chromatographic peak. The target cycle time was 500 ms. Each sample was injected in triplicate.

Table 2: Source and gas parameters for the analysis of NPS in human whole blood using the SCIEX 5500+ system.

| Parameter | Value |
|--------------------|----------|
| Polarity | Positive |
| Ion source gas 1 | 50 psi |
| Ion source gas 2 | 50 psi |
| Curtain gas | 30 psi |
| Source temperature | 600°C |
| Ion spray voltage | 1750 V |
| CAD gas | 8 |

A separate MRM-DDA-EPI method was run on a single transition for each compound with dynamic background subtraction (DBS), dynamic trap fill time (DFT), and an EPI collision energy of 35 V and spread of 15 eV for qualitative product ion spectral library purity. The acquisition MRM-DDA-EPI parameters are presented in [Table 3](#).

Table 3: QTRAP parameters for the analysis of NPS in human whole blood using the SCIEX 5500+ system.

| Parameter | Value |
|--------------------------------|----------------|
| Criteria | Small molecule |
| Maximum candidate ions | 6 |
| Intensity Threshold exceeds | 5000 cps |
| Dynamic background subtraction | True |
| Exclude former candidate ions | False |
| Scan type for survey | MRM |
| DFT enabled | True |
| Scan speed | 10,000 |
| CE [\pm CES] | 35 \pm 15 V |

Data processing: Data acquisition and processing were performed in [SCIEX OS software \(v 3.4\)](#). Quantitative analysis was performed in the Analytics module of the software and peaks were automatically integrated using the MQ4 algorithm. Calibration curves, concentration calculations and accuracy and precision statistics were automatically generated.

MS/MS spectral library comparison was performed with the MRM-DDA-EPI data. The library search algorithm was set to “Smart Confirmation Search” with results sorted by “Fit”. In the Algorithm Parameters criteria, “Precursor Mass Tolerance” was set to ± 0.4 Da, and “Use Polarity” was selected. The “Intensity Threshold” was 0.05 and the “Intensity Factor” was 5. Experimental MS/MS spectra were compared against a custom-built library that was previously generated from the individual neat standard mixtures.

Chromatographic separation of isobaric NPS groups

Chromatographic separation of isobars is important to minimize potential false positives, false negatives and poor quantitative accuracy. The NPS analyte panel contained 29 isobaric groups comprising a total of 70 compounds and therefore the LC column, mobile phases, modifiers, and gradient conditions were chosen to optimize the isobar chromatographic separation.

Overall, the method chromatographically separated 24 out of the 29 isobaric groups. **Figure 3** [top panel, "A"] shows an

example of the baseline separation of the isobaric group: ABD-BINACA N-butanoic acid, 4OH-MDMB-BICA, and 4CN-CUMYL-BINACA. Of the 5 non-chromatographically separated groups, 2 isobaric groups contained compounds with unique fragments and were, therefore, distinguished using their MS/MS spectral patterns. For example, as shown in **Figure 3** [bottom panel, "B"], the co-eluting isobaric pair of etonitazepyne and carfentanil were confirmed by their unique MS/MS spectra and library matching. For the remaining 3 isobaric groups, detection confirmation and quantitation should be performed using orthogonal chromatography conditions.




Figure 3. Separation of NPS isobaric groups using chromatography [top panel, "A"] and unique MS/MS spectra [bottom panel, "B"]. The top panel ("A") shows the baseline separation of ABD-BINACA N-butanoic acid, 4OH-MDMB-BICA, and 4CN-CUMYL-BINACA [Q1 m/z 361 Da] using the Phenomenex Kinetex C18 column. The bottom panel ("B") shows unique MS/MS spectra of the co-eluting isobars of etonitazepyne and carfentanil. The blue lines in the mass spectra represent the experimental data whereas the grey lines represent the library match from the custom-generated MS/MS library.

Quantitative performance in matrix-matched calibrators

Sensitivity, accuracy, precision, and linear dynamic range were evaluated in a series of calibrators spiked into human whole blood, processed through the protein precipitation sample preparation procedure, and analyzed using the SCIEX 5500+ system. The calibration range was from 0.1 ng/mL to 50 ng/mL except for alpha-PPP [0.01-5 ng/mL] and U-48800 [0.04-20 ng/mL].

For most NPS compounds, the linear dynamic range was 2-2.5 orders of magnitude, and a quadratic calibration curve was the best regression model. Overall, the quadratic regression relationship was good with r^2 values >0.900. For NPS with higher sensitivity, detector saturation was observed at the top two calibrators (25 and 50 ng/mL). Specifically, the following NPS had one or both transitions calibrated only up to 25 ng/mL due to detector saturation: 4-APB, 3-chlorocathinone, deschloronorketamine, 4F-pentedrone, N-methyl-hexylone, bentazepam, 3-fluoro-N-ethylbuphedrone, N-ethyl heptedrone, 5-MeO-MiPT, N-butyl hexedrone, flunitrazepam,

PCE, para-methyl AP-237, furanyl UF-17, nitrazepam, 4F-MDMB-BICA, tenocyclidine, despropionyl ortho-fluorofentanyl, ADB-BINACA, N-piperidinyl etonitazine, ADB-4EN-PINACA, 5F-EMB-PICA, 5F-BZD-POXIZID [5F-MDA-19], 4CN-CUMYL-BINACA, 4F-MDMB-BINACA, 4'-hydroxy nitazene, 5F-MDMB-PICA, ADB-PHETINACA, clonitazene. In contrast, NPSs with their actual LOQ near the 0.1 ng/mL calibrator showed linearity throughout the 0.1 to 50 ng/mL range. The observed range in linearity behavior was expected due the structural diversity of the NPS included in the panel.

Most NPS compounds were quantifiable down to 0.1 ng/mL, which represented the lowest calibrator point. The only exceptions were alpha-PPP (LOQ = 0.01 ng/mL) and U-48800 (LOQ = 0.04 ng/mL), which had a lower calibration range, and ADB-4EN-PINACA (LOQ = 0.25 ng/mL) and 4-AcO-EPT (LOQ = 5 ng/mL), which showed comparably less sensitivity. Extracted ion chromatograms (XICs) for representative NPS at the LOQ are shown in **Figure 4**. These XICs demonstrate good signal-to-noise down at the LOQ concentration for most NPSs, indicating that the actual LOQ was presumably significantly lower.




Figure 4. Extracted ion chromatograms (XICs) for representative NPS compounds in the 0.1 ng/mL calibrator. NPSs were spiked in human whole blood, processed through the protein precipitation sample preparation procedure and analyzed using the SCIEX 5500+ system.

The method accuracy and precision were evaluated in the LOQ calibrator [n=3 injections], which corresponded to 0.1 ng/mL for most NPS. The violin plot in **Figure 5** represents the distribution of the mean accuracies for all 130 NPS compounds and is a powerful tool for visualizing trends in large data sets. As shown in the violin plot, the mean accuracies were mostly between 80% and 120%, with only 4 NPSs falling outside the range. Similarly, the overall mean LOQ precision was very good, with most NPSs showing a mean precision <10 %CV [**Figure 5**]. Only 8 NPS compounds showed mean precision between 10 and 30%CV. Overall, the LOQ accuracy and precision trends demonstrate broad method applicability across the diverse panel of 130 NPS.




Figure 5. Mean accuracy and precision at the LOQ [0.1 ng/mL]. NPSs were spiked in human whole blood, processed through the protein precipitation sample preparation procedure and analyzed using the SCIEX 5500+ system.

Improved detection confidence using QTRAP technology and MS/MS library matching

It is crucial for forensic toxicology labs to obtain confident, unambiguous NPS detection in real-world samples. QTRAP instruments can acquire enhanced product ion [EPI] scans which provide high-quality MS/MS spectra for library matching and compound detection confirmation. Therefore, separate

MRM-DDA-EPI experiments were performed to acquire MS/MS spectra for the full calibrator set. The experimental MS/MS were compared against a user-generated MS/MS spectral library of reference standards using the Library Search module in the SCIEX OS software. The custom NPS library was previously generated from individual neat standard solutions.

At the lowest calibrator level [0.1 ng/mL for most NPS], positive MS/MS library matches were confirmed for 122 out of the 130





Figure 6. SCIEX OS confidence criteria [top], Results Table [middle], as well as XIC and MS/MS spectrum from MRM-DDA-EPI scan for brorphine in the 0.1 ng/mL calibrator [bottom]. Detection was confirmed through MS/MS library matching with a custom-generated NPS MS/MS library. The top portion of the figure shows the use of the qualitative flagging rules to quickly filter the Results Table for positive library matches [library match score >70].

NPS target analytes. Examples are shown in **Figure 1** for para-fluorofentanyl and **Figure 6** for brorphine. In addition, **Figure 6** shows the qualitative flagging rules filtering in the Results Table. A library Fit score >70 was considered a positive match for compound detection. The Results Table was quickly filtered using the qualitative flagging rules in the SCIEX OS software, significantly reducing the data review time. Of the 7 compounds that did not have positive matches, 2 compounds did not trigger MS/MS acquisition, and 5 compounds had poor MS/MS spectral quality due to low sensitivity and matrix interferences. In the 1 ng/mL calibrator, all NPS showed positive library matches except for 4-AcO-EPT which did not trigger the EPI scan. Overall, the method showed sufficient sensitivity to obtain good MS/MS library matches even at trace levels of NPS in human whole blood.

Conclusions

This technical note demonstrated:

- Broad applicability to NPS exhibiting a range of chemical and physical properties
- Chromatographic separation of 24 out of 29 isobaric groups, thereby minimizing false positives and false negatives. Most of the co-eluting NPSs could be distinguished by unique MS/MS spectra
- LOQs down to 0.1 ng/mL except for two compounds, demonstrating the sensitivity needed for forensic toxicology labs

- Good quantitative performance in the LOQ calibrators with mean accuracies mostly from 80 to 120% and mean precision <10%CV
- Enhanced detection confidence through the use of QTRAP technology. The EPI scans acquired high-quality MS/MS spectra for library matching against a user-generated database. 122 out of 130 NPSs showed a positive, accurate library match in the 0.1 ng/mL calibrator

References

1. Shafi, A.; Berry, A.J.; Sumnall, H.; Wood, D.M.; Tracy, D.K. New psychoactive substances: a review and updates. *Ther. Adv. Psychopharmacol.* **2020**, *10*, 1-21.
DOI: [10.1177/2045125320967197](https://doi.org/10.1177/2045125320967197)
2. Krotulski, A.J.; Mata, D.C.; Smith, C.R.; Palmquist-Orlando, K.B.; Modell, C.; Vikingsson, S.; Truver, M.T. Advances in analytical methodologies for detecting novel psychoactive substances: a review. *JAT* **2025**, *49*(3), 152-169. DOI: [10.1093/jat/bkae098](https://doi.org/10.1093/jat/bkae098)

Acknowledgements

The author would like to thank Alex Krotulski and Alberto Salomone for curating the list of relevant NPS and providing some of the standards used in these experiments.

Supporting information

Compound-specific parameters may be downloaded from SCIEX Now

The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to <https://sciex.com/diagnostics>. All other products are For Research Use Only. Not for use in Diagnostic Procedures.

Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries [see www.sciex.com/trademarks].

© 2025 DH Tech. Dev. Pte. Ltd. MKT-35341-A



Headquarters

500 Old Connecticut Path | Framingham, MA 01701
USA
Phone 508-383-7700
sciex.com

International Sales

For our office locations please call the division headquarters or refer to our website at
sciex.com/offices